Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, raised a $25M Series A (Natalie Breymeyer/Axios)

Altis Labs, an AI software company specializing in drug development, has successfully raised a $25 million Series A funding round. The company's AI model plays a crucial role in oncology trials by analyzing CT scans and generating predictions related to patient survival. This funding, as confirmed by CEO Felix Baldauf-Lenschen to Axios Pro, will further support Altis Labs' innovative work in leveraging artificial intelligence for medical advancements.